Category: ENGOT

ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in advanced/recurrent endometrial cancer

ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in advanced/recurrent endometrial cancer ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in advanced/recurrent endometrial cancer Mansoor Raza Mirza, MD Study Chair & Medical Direcor of NSGO-CTU ENGOT, NSGO-CTU & GOG-Foundation proudly announce the ground-breaking results of ENGOT-EN6-NSGO/GOG-3031/RUBY trial. The results reveal improvement in overall survival at […]

INOVATYON/ ENGOT-ov5 Trial publication

Results from the MaNGO lead study INOVATYON/ ENGOT-ov5 The Novemeber edition of the American Society of Clinical Oncology has published: INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line   With contributions […]

ENGOT Workshop in Malaga

ENGOT Workshop in Malaga The 2022 GCA edition is organized by ENGOT in cooperation with the European Network of Young Gynae Oncologists (ENYGO) and is designed to help senior investigators to experience the clinical trial leader role as well as to young clinicians to gain knowledge within the clinical trial community. arrow-icon-size3 Back To Overview

ENGOT-EN6/GOG-3031/NSGO-RUBY STUDY

Results of ENGOT-EN6/GOG-3031/NSGO-RUBY study:  A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer Results of ENGOT-EN6/GOG-3031/NSGO-RUBY study: A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer. “This is a great milestone for our […]

AGO-OVAR 17 BOOST/GINECO

Results from AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 The Novemeber edition of the American Society of Clinical Oncology has published “Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial”   ABSTRACT PURPOSE To compare standard versus extended duration of bevacizumab treatment in combination […]

OReO/ENGOT-ov38 – IGCS22 / New York

OReO/ENGOT-ov38 PRO data from the phase 3b OReO/ENGOT-ov38 trial showed no significant effect on quality of life following rechallenge with maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer. International Gynecologic Cancer Society http://ow.ly/cxCh50L0j4b #IGCS2022 #gynsm #cancer #oncology arrow-icon-size3 Back To Overview

ENGOT meeting in Berlin, Sep. 2022

ENGOT meeting 15th annaversary Berlin, Sep. 2022 NSGO-CTU’s Medical Director, Dr. Mansoor Raza Mirza and Deputy Medical Director, Kristine Madsen attended the annual ENGOT meeting in Berlin last week. Dr. Mirza is currently Chair of ENGOT. Project Manager Christina Sidsel Dalsgaard and Mia Sejer Donner (NSGO-CTU ENGOT rep.) also attended the meeting with the ENGOT operationals. Previous Next arrow-icon-size3 Back To […]

Paola-1/ENGOT – OV25 trial

Results from Paola-1 ENGOT/OV25 The October edition of The European Journal of Cancer (EJC) has published “Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial” The results were presented by Dr. Isabelle Ray-Coquard at ESMO – European Society for Medical Oncology in Paris last month. #EuropeanJournalofCancer #EJC #PAOLA #ENGOT #clinicaltrial #ovariancancer #NSGO arrow-icon-size3 Back To […]

World Ovarian Cancer Day

WORLD OVARIAN CANCER DAY Sep. 20th 2022 Today is World Ovarian Cancer Day! Annually, ovarian cancer results in more than 42,700 deaths in Europe. NSGO-CTU is currently involved in 18 Ovarian Cancer Trials in #Denmark, #Sweden, #Norway, #Finland, #Lithuania & #Estonia. See our trial overview with + 30 trials arrow-icon-size3 Back To Overview